← boardnext 2029-03-02
AUPH
Aurinia Pharmaceuticals Inc.distress 0/10 · well-funded / low risk$15.09-2%today-19% from 52w high
Immunology / Inflammation 2
Lead: Adolescent Lupus Nephritis · est. market ~$5B (approx, global)
Revenue
$78M
Liquidity
$41M
Runway
—
Shares 1y
-2%
Price & events
+1.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-5.3%
1W
-15.6%
1M
-6.5%
3M
+3.9%
6M
+64.2%
1Y
+176.9%
2Y
+33.0%
5Y
+11.4%
All
Overview
- Market Cap
- $1.94B
- Volume
- 48.18K
- 52 Week Range
- $8.62 – $18.62
- Total Shares
- 128.60M
- Float Shares
- 126.24M
- Short %
- 8.26%
- % Held by Insiders
- 7.53%
- % Held by Institutions
- 60.33%
- RVOL
- 0.03x
- Beta
- 1.42
Pipeline stages · 2 programs
Aritinercept
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
voclosporin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-03-02 Estimated 50% readout ~2029-04-16 | Phase 1/2 | Aritinercept | Myasthenia Gravis, Generalized | — | recruiting |
| 2025-07-04 | Phase 3 | voclosporin | Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | 4 | terminated |
| 2025-07-03 | Phase 3 | Voclosporin | Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | 9 | terminated |
Catalyst news & presentations · 2
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-03-30partnershipAurinia entered into merger agreement to acquire Kezar Life Sciences for $6.955 per share plus contingent value rightsSEC 8-K
Approved drugs (1)
- LUPKYNISVOCLOSPORIN2021 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $17 (+13% upside) · 7 analysts
- 2025-12-03Leerink PartnersOutperform → Market Perform
- 2025-11-07JefferiesHold → Buy
- 2025-11-05RBC CapitalOutperform → Sector Perform
- 2025-08-01RBC CapitalOutperform
- 2024-09-16Cantor FitzgeraldOverweight
- 2024-09-09Cantor FitzgeraldOverweight
Competitors — Adolescent Lupus Nephritis
- none identified
Recent news
- 2026-07-23AUPH Q2'26 Earnings: revenue estimate is 80.45M USD - TradingView
- 2026-07-23Liquidity Mapping Around (AUPH) Price Events - Stock Traders Daily
- 2026-07-22Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary - Quartr
- 2026-07-20Aurinia Pharmaceuticals (AUPH) Proxy filing Summary - Quartr
- 2026-07-19Aurinia Pharmaceuticals (AUPH) Q1 2026 earnings summary - Quartr
- 2026-07-19Aurinia Pharmaceuticals (AUPH) Proxy Filing Summary - Quartr
- 2026-07-19Aurinia Pharmaceuticals (AUPH) 2024 Cantor Fitzgerald Global Healthcare Conference summary - Quartr
- 2026-07-19Aurinia Pharmaceuticals (AUPH) Proxy filing Summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.